Merck Launches 2nd Biosimilar Rival To J&J's Remicade
Merck & Co. Inc. on Monday launched a biosimilar version of Johnson & Johnson's blockbuster biologic Remicade, marking the first time that two lower-cost biosimilars are available for the same product...To view the full article, register now.
Already a subscriber? Click here to view full article